# Avraham Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avraham-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Yavneh, Israel
- Website: www.avphar.com
- Total disclosed funding: $9M
- Latest round: Series A (Apr 15, 2010)
- Investors on record: 3

## About

Based in Israel and founded in 2010 by founder Vincent R. Zurawski Avraham Pharmaceuticals Ltd. is a developer of a molecule for the treatment of Alzheimer’s disease, mild cognitive impairment and other neurodegenerative diseases. In February 2016, Avraham Pharmaceuticals raised USD 4 million in funding from investors Yissum Research Development Company Ltd., Pontifax, Clal Biotechnology Industries Ltd., Integra Holdings, and Technion Research and Development Foundation Ltd.

Avraham Pharmaceuticals is developing ladostigil to address the unmet medical need for an effective treatment for MCI. This is an oral delivery method and the advanced development stage of ladostigil.

## Funding rounds

- Series A, Apr 15, 2010, $9M — Pontifax Venture Capital, Clal Biotechnology, Yissum Research Development

## Investors

- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series A
- Clal Biotechnology (https://capitalatlas.ai/funds/clal-biotechnology) — Series A
- Yissum Research Development — Series A